Fractyl Health (GUTS) fell 27% in after-hours trade after announcing a stock offering. Yet retail sentiment surged on strong real-world Revita data showing sustained weight loss and HbA1c reduction in type 2 diabetes patients two years post-procedure. Traders expect a rebound as pivotal US trials progress.